hgh and cancer patients rhGH therapy in GHD adults has proved to be safe regarding cancer risk - DoesHGHcause prostatecancer growth hormone replacement therapy could reduce risk of cancer A Comprehensive Review: HGH and Cancer Patients - Understanding the Complex Relationship

DoesHGHcause prostatecancer The interplay between human growth hormone (HGH) and cancer is a multifaceted area of medical research, with various studies exploring both potential risks and therapeutic implications.作者：LE Harrison·1996·被引用次数：40—The role ofhuman growth hormone(hGH) as a nutritional adjunct forcancer patientsis controversial because of its potential mitogenic effects on tumor growth. While early research and specific conditions like acromegaly (characterized by high GH levels) have drawn attention to potential associations, more recent data suggests a nuanced picture, particularly concerning recombinant human growth hormone (rhGH) therapy in different patient populations. This article delves into the current understanding of HGH and cancer patients, examining the evidence for cancer risks, safety considerations, and the role of growth hormone in the context of cancer treatment and survivorship.

The Historical Context and Evolving Understanding of HGH and Cancer

The hypothesis linking growth hormone to carcinogenesis has existed for decadesthe health risks of human growth hormone. The rationale often stems from the known anabolic and proliferative effects of GH. Early studies involving human growth hormone (hGH), particularly those derived from cadavers, indicated potentially increased risks for certain cancers. For instance, a 2002 study by Swerdlow et al作者：AJ Swerdlow·2002·被引用次数：364—Patientstreated with human pituitarygrowth hormonehad significantly raised risks of mortality fromcanceroverall.. identified a significantly raised risk of mortality from cancer overall in patients treated with human pituitary growth hormoneSafety of growth hormone replacement in survivors of cancer .... Similarly, a 2003 study by Preece et al. reported a standardized mortality ratio of 2.8 for cancer overall (95% CI 1.3-5.1) in a cohort treated with hGH. These findings contributed to a cautious approach regarding GH therapy.

However, it's crucial to differentiate between different sources and applications of growth hormone.Studies show that lowering IGF-1 by 50% decreasescancerrisk significantly and that increased levels of IGF-1 are linked with highercancerrisk. The advent of recombinant human growth hormone (rhGH) has revolutionized treatment, offering a safer and more consistent supply. Current evidence, particularly from reviews like those published in 2023 and 2022 by Boguszewski and colleagues, suggests that rhGH therapy in GHD adults has proved to be safe regarding cancer risk when administered according to established guidelines and respecting contraindications. This distinction is vital, as many past concerns may be attributed to older treatment modalities.

Specific Conditions and Cancer Associations

Acromegaly, a condition characterized by excessive production of growth hormone, has been consistently linked to an increased risk of certain cancers. A 2025 study highlighted that individuals with acromegaly have a significantly higher risk of developing various types of cancer. This association is believed to be due to persistently high GH levels and their downstream effects, including elevated levels of Insulin-like Growth Factor 1 (IGF-1). In fact, studies indicate that lowering IGF-1 by 50% can decrease cancer risk significantly, and that increased levels of IGF-1 are indeed linked with higher cancer riskGrowth hormone treatment and risk of malignancy - PMC - NIH.

Conversely, the link between growth hormone replacement therapy in patients with growth hormone deficiency (GHD) and cancer development is less clear and often shows no significant association. While some studies have pointed to a slightly elevated risk of certain cancers like bone and thyroid cancers in individuals treated with GH during childhood for conditions like GHD, Short Stature (SGA), or Idiopathic Short Stature (ISS), systematic reviews and extensive studies have often found no clear association with malignant neoplastic events in early to mid-adulthood or overall mortality and cancer incidence. A 2022 study by He et al., for instance, found no significant association between the dose of rhGH and mortality and cancer incidence, making causality less likely.

HGH, Cancer Survivors, and Children

A significant area of inquiry revolves around the safety of growth hormone (GH) treatment for cancer survivors, particularly pediatric cancer survivors. Many patients who undergo extensive cancer treatment, such as radiation therapy to the brain or pituitary gland, can develop growth hormone deficiency. These treatments can damage the pituitary gland, impairing its ability to produce sufficient GHGrowth hormone treatment and risk of malignancy - PMC - NIH. A 2021 review concluded that it is safe to administer growth hormone (GH) treatment to pediatric cancer survivors, despite historical concerns. Current evidence reviewed from expert workshops does not support an association between GH replacement and primary tumor or cancer recurrence in these individualsCertaincancertreatments can cause the pituitary gland to not make enoughgrowth hormone. These include:cancer treatmentbefore you reached your adult height, .... This is critical, as restoring adequate GH levels can significantly improve their quality of life and facilitate normal development.

For children undergoing growth hormone therapy for conditions like GHD, SGA, or ISS, the long-term risks of cancer have been extensively studied. A 2024 study by Tidblad et al. found no association was found between rhGH treatment during childhood for GHD, SGA, or ISS and malignant neoplastic events in early to mid-adulthood. Furthermore, a 2024 study on somatropin injections in children found a low risk of developing diabetes and cancer, comparable to the general population. These findings underscore the safety of rhGH in pediatric populations when used appropriately作者：AJ Swerdlow·2017·被引用次数：181—There was significantly raised risk of both cancer mortality and incidencefor cancers of the bone, kidney, central nervous system (CNS), and thyroid..

Potential Therapeutic Roles and Future Directions

Beyond direct risks, research is also exploring the potential role of growth hormone action as a target in cancer therapy itself. Some studies suggest that GH action is implicit in escalating several cancer-associated events, leading to investigations into therapies that could block GH signaling pathways to slow tumor cell proliferation. Conversely, some research even suggests that growth hormone replacement therapy could reduce risk of cancer in adults with growth hormone deficiency, though this remains an area requiring further investigation.Effect of Human Growth Hormone on Human Pancreatic ...

It's important to note that the abuse of human growth hormone (hGH) or IGF-1 for non-medical purposes, such as anti-aging or athletic enhancement, carries significant risksSafety of long-term use of daily and long-acting growth .... Prolonged exposure to high levels of human growth hormone can lead to irreversible side effects. Therefore, responsible medical use under strict supervision is paramount.

Conclusion

The relationship between HGH and cancer patients is intricate and has evolved with scientific understanding. While historical data and conditions of GH excess like acromegaly have raised concerns, contemporary research, particularly regarding rhGH therapy, generally indicates a favorable safety profile for patients with GHD, including pediatric cancer survivors requiring treatment.Cancer Risks in Patients Treated With Growth Hormone in ... The consensus is moving towards recognizing that GH therapy, when medically indicated and appropriately managed, does not typically pose a significant risk for the development or recurrence of cancer, and can be crucial for the well-being of individuals with GH deficiencies. Ongoing research continues to refine our understanding of these complex interactions, promising further insights into both potential risks and therapeutic applications.